This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO-Asia, Singapore 22-24 November 2019

A Phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: a biomarker analysis

Rafael Rosell, Artem Poltoratskiy, Maximilian Hochmair, Konstantin K. Laktionov, Rodryg Ramlau, Jana Skrickova, Simona Rizzato, Paolo Bidoli, Dariusz Kowalski, Laura Clementi, Agnieszka Cseh, Filippo de Marinis

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

The value of real-world evidence to clinical practice

Real-world evidence complements clinical trials by providing information on the effectiveness and side-effect profile of therapies in patients treated in routine clinical practice.

The value of real-world evidence to clinical practice

RELATED INFORMATION

Afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

Related information

NSCLC AFATINIB CLINICAL TRIALS / STUDIES

FOR HEALTHCARE PROFESSIONALS ONLY.